ArticleEndocrinology2016
The PGE2 EP3 Receptor Regulates Diet-Induced Adiposity in Male Mice.
Open access · bronzeAbstract read
In one paragraph
Article in Endocrinology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 74 citations in OpenAlex.
- Physiological Significance and Functions of AA.Reviews of physiology, biochemistry and pharmacology · 2027Review
- Persistent prostaglandin E2 upregulation and hormonal multi-resistance: A hypothesis for long COVID.Biochemistry and biophysics reports · 2026Article
- PGEThe Journal of investigative dermatology · 2026Article
- Experimental Research Progress of mPGES-1 Inhibitor 2,5- dimethylcelecoxib in Various Diseases.Current medicinal chemistry · 2026Review
- Deletion of EP3 prostaglandin receptor in murine macrophages aggravates diet-induced obesity by suppressing SPARC.The EMBO journal · 2025Article
- Article
- snRNA-seq of adipose tissues reveals the potential cellular and molecular mechanisms of cold and disease resistance in Mongolian cattle.BMC genomics · 2024Article
- GαJournal of the Endocrine Society · 2024Article
- The prostaglandin EAmerican journal of physiology. Endocrinology and metabolism · 2024Article
- Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease.JHEP reports : innovation in hepatology · 2024Review
- Article
- Growth hormone insensitivity and adipose tissue: tissue morphology and transcriptome analyses in pigs and humans.Pituitary · 2023Article
- Review
- BMPER is a marker of adipose progenitors and adipocytes and a positive modulator of adipogenesis.Communications biology · 2023Article
- The Natriuretic Peptide System: A Single Entity, Pleiotropic Effects.International journal of molecular sciences · 2023Review
- Exploring Visceral and Subcutaneous Adipose Tissue Secretomes in Human Obesity: Implications for Metabolic Disease.Endocrinology · 2022Article
- PGEThe EMBO journal · 2022Article
- Participation of lipopolysaccharide in hyperplasic adipose expansion: Involvement of NADPH oxidase/ROS/p42/p44 MAPK-dependent Cyclooxygenase-2.Journal of cellular and molecular medicine · 2022Article
- Pharmacological blockade of the EP3 prostaglandin EMolecular metabolism · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Ryan P CeddiaDepartment of Veterans Affairs (A.C.P., M.G., R.M.B.), Tennessee Valley Health Authority, and Department of Medicine (R.M.B.), Division of Nephrology and Hypertension; Departments of Pharmacology (R.P.C., G.M., R.M.B.) and Cell and Developmental Biology (D.L., D.W.T., M.G.); Department of Medicine (M.F.M., G.P., A.C.P., M.G.), Division of Diabetes, Endocrinology, and Metabolism; and Departments of Molecular Physiology and Biophysics (B.A.C., A.C.P., O.P.G., M.G.) and Pathology, Microbiology, and Immunology (K.L.B.), Vanderbilt University Medical Center, Nashville, Tennessee 37232.
DaeKee LeeDepartment of Veterans Affairs (A.C.P., M.G., R.M.B.), Tennessee Valley Health Authority, and Department of Medicine (R.M.B.), Division of Nephrology and Hypertension; Departments of Pharmacology (R.P.C., G.M., R.M.B.) and Cell and Developmental Biology (D.L., D.W.T., M.G.); Department of Medicine (M.F.M., G.P., A.C.P., M.G.), Division of Diabetes, Endocrinology, and Metabolism; and Departments of Molecular Physiology and Biophysics (B.A.C., A.C.P., O.P.G., M.G.) and Pathology, Microbiology, and Immunology (K.L.B.), Vanderbilt University Medical Center, Nashville, Tennessee 37232.
Matthew F MaulisDepartment of Veterans Affairs (A.C.P., M.G., R.M.B.), Tennessee Valley Health Authority, and Department of Medicine (R.M.B.), Division of Nephrology and Hypertension; Departments of Pharmacology (R.P.C., G.M., R.M.B.) and Cell and Developmental Biology (D.L., D.W.T., M.G.); Department of Medicine (M.F.M., G.P., A.C.P., M.G.), Division of Diabetes, Endocrinology, and Metabolism; and Departments of Molecular Physiology and Biophysics (B.A.C., A.C.P., O.P.G., M.G.) and Pathology, Microbiology, and Immunology (K.L.B.), Vanderbilt University Medical Center, Nashville, Tennessee 37232.
Bethany A CarboneauDepartment of Veterans Affairs (A.C.P., M.G., R.M.B.), Tennessee Valley Health Authority, and Department of Medicine (R.M.B.), Division of Nephrology and Hypertension; Departments of Pharmacology (R.P.C., G.M., R.M.B.) and Cell and Developmental Biology (D.L., D.W.T., M.G.); Department of Medicine (M.F.M., G.P., A.C.P., M.G.), Division of Diabetes, Endocrinology, and Metabolism; and Departments of Molecular Physiology and Biophysics (B.A.C., A.C.P., O.P.G., M.G.) and Pathology, Microbiology, and Immunology (K.L.B.), Vanderbilt University Medical Center, Nashville, Tennessee 37232.
David W ThreadgillDepartment of Veterans Affairs (A.C.P., M.G., R.M.B.), Tennessee Valley Health Authority, and Department of Medicine (R.M.B.), Division of Nephrology and Hypertension; Departments of Pharmacology (R.P.C., G.M., R.M.B.) and Cell and Developmental Biology (D.L., D.W.T., M.G.); Department of Medicine (M.F.M., G.P., A.C.P., M.G.), Division of Diabetes, Endocrinology, and Metabolism; and Departments of Molecular Physiology and Biophysics (B.A.C., A.C.P., O.P.G., M.G.) and Pathology, Microbiology, and Immunology (K.L.B.), Vanderbilt University Medical Center, Nashville, Tennessee 37232.
Greg PoffenbergerDepartment of Veterans Affairs (A.C.P., M.G., R.M.B.), Tennessee Valley Health Authority, and Department of Medicine (R.M.B.), Division of Nephrology and Hypertension; Departments of Pharmacology (R.P.C., G.M., R.M.B.) and Cell and Developmental Biology (D.L., D.W.T., M.G.); Department of Medicine (M.F.M., G.P., A.C.P., M.G.), Division of Diabetes, Endocrinology, and Metabolism; and Departments of Molecular Physiology and Biophysics (B.A.C., A.C.P., O.P.G., M.G.) and Pathology, Microbiology, and Immunology (K.L.B.), Vanderbilt University Medical Center, Nashville, Tennessee 37232.
Ginger MilneDepartment of Veterans Affairs (A.C.P., M.G., R.M.B.), Tennessee Valley Health Authority, and Department of Medicine (R.M.B.), Division of Nephrology and Hypertension; Departments of Pharmacology (R.P.C., G.M., R.M.B.) and Cell and Developmental Biology (D.L., D.W.T., M.G.); Department of Medicine (M.F.M., G.P., A.C.P., M.G.), Division of Diabetes, Endocrinology, and Metabolism; and Departments of Molecular Physiology and Biophysics (B.A.C., A.C.P., O.P.G., M.G.) and Pathology, Microbiology, and Immunology (K.L.B.), Vanderbilt University Medical Center, Nashville, Tennessee 37232.
Kelli L BoydDepartment of Veterans Affairs (A.C.P., M.G., R.M.B.), Tennessee Valley Health Authority, and Department of Medicine (R.M.B.), Division of Nephrology and Hypertension; Departments of Pharmacology (R.P.C., G.M., R.M.B.) and Cell and Developmental Biology (D.L., D.W.T., M.G.); Department of Medicine (M.F.M., G.P., A.C.P., M.G.), Division of Diabetes, Endocrinology, and Metabolism; and Departments of Molecular Physiology and Biophysics (B.A.C., A.C.P., O.P.G., M.G.) and Pathology, Microbiology, and Immunology (K.L.B.), Vanderbilt University Medical Center, Nashville, Tennessee 37232.
Alvin C PowersDepartment of Veterans Affairs (A.C.P., M.G., R.M.B.), Tennessee Valley Health Authority, and Department of Medicine (R.M.B.), Division of Nephrology and Hypertension; Departments of Pharmacology (R.P.C., G.M., R.M.B.) and Cell and Developmental Biology (D.L., D.W.T., M.G.); Department of Medicine (M.F.M., G.P., A.C.P., M.G.), Division of Diabetes, Endocrinology, and Metabolism; and Departments of Molecular Physiology and Biophysics (B.A.C., A.C.P., O.P.G., M.G.) and Pathology, Microbiology, and Immunology (K.L.B.), Vanderbilt University Medical Center, Nashville, Tennessee 37232.
Owen P McGuinnessDepartment of Veterans Affairs (A.C.P., M.G., R.M.B.), Tennessee Valley Health Authority, and Department of Medicine (R.M.B.), Division of Nephrology and Hypertension; Departments of Pharmacology (R.P.C., G.M., R.M.B.) and Cell and Developmental Biology (D.L., D.W.T., M.G.); Department of Medicine (M.F.M., G.P., A.C.P., M.G.), Division of Diabetes, Endocrinology, and Metabolism; and Departments of Molecular Physiology and Biophysics (B.A.C., A.C.P., O.P.G., M.G.) and Pathology, Microbiology, and Immunology (K.L.B.), Vanderbilt University Medical Center, Nashville, Tennessee 37232.
Maureen GannonDepartment of Veterans Affairs (A.C.P., M.G., R.M.B.), Tennessee Valley Health Authority, and Department of Medicine (R.M.B.), Division of Nephrology and Hypertension; Departments of Pharmacology (R.P.C., G.M., R.M.B.) and Cell and Developmental Biology (D.L., D.W.T., M.G.); Department of Medicine (M.F.M., G.P., A.C.P., M.G.), Division of Diabetes, Endocrinology, and Metabolism; and Departments of Molecular Physiology and Biophysics (B.A.C., A.C.P., O.P.G., M.G.) and Pathology, Microbiology, and Immunology (K.L.B.), Vanderbilt University Medical Center, Nashville, Tennessee 37232.
Richard M BreyerDepartment of Veterans Affairs (A.C.P., M.G., R.M.B.), Tennessee Valley Health Authority, and Department of Medicine (R.M.B.), Division of Nephrology and Hypertension; Departments of Pharmacology (R.P.C., G.M., R.M.B.) and Cell and Developmental Biology (D.L., D.W.T., M.G.); Department of Medicine (M.F.M., G.P., A.C.P., M.G.), Division of Diabetes, Endocrinology, and Metabolism; and Departments of Molecular Physiology and Biophysics (B.A.C., A.C.P., O.P.G., M.G.) and Pathology, Microbiology, and Immunology (K.L.B.), Vanderbilt University Medical Center, Nashville, Tennessee 37232.
Tennessee Department of Health · USTennessee Valley Authority · USVanderbilt University Medical Center · US
Funding
Coordinating Center for Beta Cell Biology ConsortiumU01DK072473 · NIDDK · VANDERBILT UNIVERSITY · PI MAGNUSON, MARK A · 2005 to 2014
$61.0MThe Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4MTranslational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9MVanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI OWEN P MCGUINNESS · 2012 to 2026
$29.3MTRANSGENIC MOUSE/ ES CELL SHARES RESOURCESP60DK020593 · NIDDK · VANDERBILT UNIVERSITY · PI MCGUINNESS, OWEN P · 1986 to 2011
$28.1MVanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9MMolecular Mechanisms of Human and Murine Beta Cell Proliferation and RegenerationU01DK089572 · NIDDK · VANDERBILT UNIVERSITY · PI GREINER, DALE LESLIE, HARLAN, DAVID MARSHALL · 2010 to 2014
$8.4MVanderbilt Mouse Metabolic Phenotyping CenterU2CDK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2016 to 2021
$6.3MTraining Program in Stem Cell and Regenerative Developmental BiologyT32HD007502 · NICHD · VANDERBILT UNIVERSITY · PI WRIGHT, CHRISTOPHER V · 1997 to 2022
$5.4MMolecular Mechanisms of Physiologic Beta Cell Growth in Juvenile Human PancreasUC4DK104211 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KIM, SEUNG K, POWERS, ALVIN C · 2014 to 2015
$4.0MRegulation of Renal Function by PGE2 and PGF2a ReceptorsR01DK037097 · NIDDK · VANDERBILT UNIVERSITY · PI BREYER, RICHARD M. · 1986 to 2011
$3.9MIslet Biology in Cystic Fibrosis Related DiabetesR01DK097829 · NIDDK · PACIFIC NORTHWEST RESEARCH INSTITUTE · PI AGUILAR-BRYAN, LYDIA, POWERS, ALVIN C · 2012 to 2016
$2.9MBLRD VA I01 BX000616BLRD VA I01 BX000666BLRD VA I01 BX000990NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1TR000445NICHD NIH HHS T32 HD007502NICHD NIH HHS T32-HD05702NIDDK NIH HHS DK020593NIDDK NIH HHS DK059637NIDDK NIH HHS DK097829NIDDK NIH HHS DK104211NIDDK NIH HHS DK37097NIDDK NIH HHS DK46205NIDDK NIH HHS DK69603NIDDK NIH HHS DK72473NIDDK NIH HHS DK89572NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK058404NIDDK NIH HHS P60 DK020593NIDDK NIH HHS R01 DK037097NIDDK NIH HHS R01 DK046205NIDDK NIH HHS R01 DK069603NIDDK NIH HHS R01 DK097829NIDDK NIH HHS U01 DK072473NIDDK NIH HHS U01 DK089572NIDDK NIH HHS U24 DK059637NIDDK NIH HHS UC4 DK104211
Abstract
Mice carrying a targeted disruption of the prostaglandin E2 (PGE2) E-prostanoid receptor 3 (EP3) gene, Ptger3, were fed a high-fat diet (HFD), or a micronutrient matched control diet, to investigate the effects of disrupted PGE2-EP3 signaling on diabetes in a setting of diet-induced obesity. Although no differences in body weight were seen in mice fed the control diet, when fed a HFD, EP3(-/-) mice gained more weight relative to EP3(+/+) mice. Overall, EP3(-/-) mice had increased epididymal fat mass and adipocyte size; paradoxically, a relative decrease in both epididymal fat pad mass and adipocyte size was observed in the heaviest EP3(-/-) mice. The EP3(-/-) mice had increased macrophage infiltration, TNF-α, monocyte chemoattractant protein-1, IL-6 expression, and necrosis in their epididymal fat pads as compared with EP3(+/+) animals. Adipocytes isolated from EP3(+/+) or EP3(-/-) mice were assayed for the effect of PGE2-evoked inhibition of lipolysis. Adipocytes isolated from EP3(-/-) mice lacked PGE2-evoked inhibition of isoproterenol stimulated lipolysis compared with EP3(+/+). EP3(-/-) mice fed HFD had exaggerated ectopic lipid accumulation in skeletal muscle and liver, with evidence of hepatic steatosis. Both blood glucose and plasma insulin levels were similar between genotypes on a control diet, but when fed HFD, EP3(-/-) mice became hyperglycemic and hyperinsulinemic when compared with EP3(+/+) fed HFD, demonstrating a more severe insulin resistance phenotype in EP3(-/-). These results demonstrate that when fed a HFD, EP3(-/-) mice have abnormal lipid distribution, developing excessive ectopic lipid accumulation and associated insulin resistance.
Indexed as
AdiposityAdipose Tissue, WhiteAnimalsCell SizeCrosses, GeneticDiabetes Mellitus, Type 2Diet, High-FatInsulin ResistanceLipid MetabolismLiverMacrophage ActivationMaleMice, Inbred C57BLMice, KnockoutMuscle, SkeletalNecrosisPtger3 protein, mouseReceptors, Prostaglandin E, EP3 Subtype
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.